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Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally
HIV-1-infected woman
Maraviroc (MVC), a C-C chemokine receptor type five
(CCR5) antagonist, was approved as part of combination
antiretroviral therapy (cART) in 2007, for use in
treatment-experienced adults infected with CCR5-
tropic HIV-1 [1]. Whilst, with current treatment
strategies, such as maternal cART, low rates of
mother-to-child transmission (MTCT) have been
reported, in high-income countries, breastfeeding is
not recommended because of the potential MTCT risk.
However, since 2017, European [2] and United States [3]
guidelines have acknowledged that some HIV-infected
women may wish to breastfeed, and should be given
appropriate support in this decision. Whilst data exist
describing the transfer of NRTI, NNRTI, and protease
inhibitors to breastfed infants [4,5], the pharmacokinetics
and safety of MVC in lactating women and their breastfed
infants have not been reported. Here, we present the first
case of MVC in a breastfeeding mother.
A 36-year-old perinatally HIV-1-infected woman
received MVC (150mg twice daily), lamivudine
(150mg twice daily) and lopinavir/ritonavir (400/
100mg twice daily). Her plasma HIV-RNA has remained
undetectable with a CD4þ count above 500 cells/ml on
this regimen for over a decade.
In 2018, at 38þ4 weeks of gestation, she delivered a
healthy girl (2710 g, 49 cm, head circumference 35 cm,
APGAR score 10 at 5min). Standard neonatal chemo-
prophylaxis with oral zidovudine (4mg/kg twice daily)
for 14 days was given according to German–Austrian
guidelines [6]. Although not recommended, breastfeed-
ing was chosen. Exclusive breastfeeding continued until 6
months of age, with complete weaning by 7 months.
Clinical and laboratory assessment at 2, 4, and 8 weeks,
and 3, 6, 9, and 12 months after birth revealed normal
development. Full blood cell count, renal, and liver
parameters remained within normal range. HIV-DNA
PCR results were consistently negative, and at 12 months
of age, an HIV antibody test was negative.
At 5 months postpartum, a 12-h pharmacokinetic
sampling of maternal plasma and breastmilk was
performed to assess the breastmilk transfer and estimate
infant exposure to MVC. After approval by the local
ethics committee of the Charite University Medicine
Berlin, the mother gave her informed consent. Paired
maternal plasma and breastmilk samples were obtained
predose (0 h), and 1, 2, 4, 6, 8, and 12 h following
observed dosing. Thirteen days later, one single plasma
sample from the still exclusively breastfed infant was
obtained during a routine follow-up visit. Samples were
frozen at 30 8C until shipment on dry ice to the
laboratory (University of Liverpool, UK) for analysis.
Plasma concentrations of MVC were determined by
validated liquid chromatography tandem mass spectrome-
trymethod as previously described [7], with amodification
for breastmilk. Briefly, the standards and quality control
samples were prepared by spiking known concentration of
drugs (TRC, Ontario, Canada) into breastmilk (donated
by consenting volunteers through the UK Northwest
Milkbank with ethics approval) to obtain a calibration
curve (range 2.5–2500 ng/ml). MVC stable isotope was
used as internal control to minimize matrix effect.
Interday and intraday precision measured at the quality
control levels were 5.60% (3.71–6.72) and 3.04% (2.00–
4.40), respectively (mean, range). Interday and intraday
accuracy were 0.84% (7.02–6.99) and 3.30% (2.78 to
10.61), respectively. Mean recovery at all quality control
levels was 98.68% (SD, 5.69%).
The plasma MVC pharmacokinetic profile in the mother
(Fig. 1) was comparable with published data for
postpartum women [8], with full results reported in
the legend to Fig. 1. MVC was undetectable in the single
infant sample.
Fig. 1. Maraviroc maternal plasma and breastmilk concen-
tration time-profiles at 5 months postpartum. Maraviroc
concentrations in plasma and breastmilk measured by vali-
dated liquid chromatography tandem mass spectrometry as
described in the case report. The AUC0–12 h for maraviroc in
plasma was 3790 h ng/ml with a Cmax of 780 ng/ml reached
after 1 h. The breastmilk AUC0–12 h was 2317 h ng/ml with a
Cmax of 415 ng/ml reached after 2 h. The milk-to-plasma
(M : P) ratio of AUC0–12 h was 0.61.
ISSN 0269-9370 Copyright Q 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the
Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. 2443
A significant breastmilk transfer of MVC was demon-
strated, with a milk-to-plasma (M :P) ratio of 0.61,
consistent with studies in lactating rats, which indicated
that MVC is extensively secreted into rat milk [9]. MVC is
licensed for children (2 years and older) weighing at least
10 kg, at a starting dose of 50mg. Assuming an infant milk
intake of 150ml/kg/day, we estimate a daily MVC
ingestion of less than 2mg in this 6.5 kg infant. Concerns
relating to breastmilk exposure of antiretroviral drugs relate
to both infant toxicity and the potential for HIV drug
resistance to develop, shouldMTCToccur in the presence
of low drug concentrations. Although MVC was not
detected in the infant, it should be noted that the lower
limit of quantification of the assay (2.5 ng/ml) is above the
IC90 (0.57 ng/ml) [10]; low, but clinically relevant infant
concentrations were possible. Data from a single case must
be interpretedwith caution andmore data regardingMVC
in breastfeeding mother-infant pairs are needed.
In conclusion, there is significant penetration of MVC
into breastmilk with a M : P ratio of 0.61, but MVC was
undetectable in the breastfed infant.
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Symptomatic cerebrospinal fluid HIV escape syndrome in a patient on highly active antiretroviral therapy
and suppressed plasma viral load
We read with interest the article by Peluso et al. [1]
presenting 10 cases of cerebrospinal fluid (CSF)-HIV
escape syndrome describing their clinical, laboratory, and
imaging findings. We report a case of symptomatic CSF-
HIV escape syndrome that shares similar clinical and
laboratory findings and discuss the possible overlap of the
entity with CD8þ-cell encephalitis.
A 53-year-old man with a 20-year history of highly active
antiretroviral therapy for HIV, presented with a subacute
onset of altered mental status and motor weakness. The
patient was compliant with medical therapy and had a
CD4þ greater than 300 cells/ml for years. On admission,
he had a CD4þ count of 292 cells/ml and a plasma viral
load of 82 copies/ml. Brain MRI demonstrated mild
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